Patents by Inventor Yvette Van Kooyk
Yvette Van Kooyk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160361398Abstract: The disclosure is in the field of immunology and provides means and methods for the treatment of multiple sclerosis. More in particular, the disclosure relates to means and methods for inducing immune tolerance to an antigen, wherein the antigen is covalently attached to a sialylated oligosaccharide, in particular, 6?-sialyl-N-acetyllactosamine. More in particular, the disclosure provides means and methods for inducing immune tolerance against an antigen derived from myelin, such as a myelin component, such as myelin oligodendrocyte glycoprotein, a well-known target in experimental autoimmune encephalomyelitis, a murine multiple sclerosis model.Type: ApplicationFiled: June 10, 2015Publication date: December 15, 2016Inventors: Yvette Van Kooyk, Wendy Wilhelmina Josephina Unger
-
Patent number: 9180182Abstract: The invention is in the field of molecular immunology, more in particular in the field of medical treatment of animals such as humans suffering from unwanted immune reactions. The invention relates to methods for the treatment of unwanted immune reactions and provides means and methods for suppressing an immune response. The present invention relates in particular to regulatory T cells and methods of long-term, culture-expanding, activating and using same in immunotherapy and for the suppression of autoimmune responses, allergies and inflammatory diseases. The invention provides a sia alpha 2,3-conjugated antigen for use in the suppression of an immune response in a patient in need of such a treatment.Type: GrantFiled: December 15, 2011Date of Patent: November 10, 2015Assignee: VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIJK ONDER WIJSInventors: Yvette van Kooyk, Wendy Unger
-
Publication number: 20140072593Abstract: The invention is in the field of molecular immunology, more in particular in the field of medical treatment of animals such as humans suffering from unwanted immune reactions. The invention relates to methods for the treatment of unwanted immune reactions and provides means and methods for suppressing an immune response. The present invention relates in particular to regulatory T cells and methods of long-term, culture-expanding, activating and using same in immunotherapy and for the suppression of autoimmune responses, allergies and inflammatory diseases. The invention provides a sia alpha 2,3-conjugated antigen for use in the suppression of an immune response in a patient in need of such a treatment.Type: ApplicationFiled: December 15, 2011Publication date: March 13, 2014Applicant: VERENIGING VOOR CHRISTELIJK WETENSCHAPPELIJK ONDERWIJSInventors: Yvette Van Kooyk, Wendy Unger
-
Patent number: 8309097Abstract: C-type lectins are involved in the binding of many different types of carbohydrates. Considering their diversity in kind and expression of different types of cells, the influence of such binding is very diverse and dependent among others on the type of cell, the environment of the cell and the type of carbohydrate bound. In the present invention new carbohydrate specificities of C-type lectins are disclosed. Interference with this binding property has uses in the prevention of pathogen binding and also in influencing signaling pathways in the C-type lectin containing cell, particularly in Toll like receptor expressing cells such as dendritic cells. Also provided is the use of the carbohydrate specificity to enhance antigen presentation by antigen presenting cells and to manipulate migration of C-type lectin containing cells and the interaction of C-type lectin expressing cells with cellular ligands on neighboring cells.Type: GrantFiled: November 7, 2003Date of Patent: November 13, 2012Assignee: Vereniging voor Christelijk Wetenschappelijk OnderwijsInventors: Teunis Bernard Herman Geijtenbeek, Yvette van Kooyk
-
Publication number: 20120251557Abstract: The present invention provides, among others, means and methods for detecting terminal GalNAc-containing molecules. A preferred molecule for detecting the structures is a molecule comprising a carbohydrate binding part of MGL.Type: ApplicationFiled: April 10, 2012Publication date: October 4, 2012Applicant: VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS, WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORGInventors: Sandra Johanna Van Vliet, Yvette van Kooyk
-
Patent number: 8105599Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: GrantFiled: July 23, 2003Date of Patent: January 31, 2012Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard Herman Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Patent number: 8058400Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: GrantFiled: October 22, 2007Date of Patent: November 15, 2011Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard H. Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Publication number: 20100028418Abstract: The present invention provides among others means and methods for detecting terminal GalNAc containing molecules. A preferred molecule for detecting said structures is a molecule comprising a carbohydrate binding part of MGL.Type: ApplicationFiled: July 10, 2007Publication date: February 4, 2010Inventors: Sandra Johanna van Vliet, Yvette van Kooyk
-
Publication number: 20080160041Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: ApplicationFiled: October 22, 2007Publication date: July 3, 2008Inventors: Carl Gustav Figdor, Teunis Bernard Herman Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Patent number: 7285642Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: GrantFiled: July 23, 2003Date of Patent: October 23, 2007Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard Herman Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Patent number: 7148329Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of auto-immune diseases, the treatment of allergy, and/or for inhibiting HIV infection. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins.Type: GrantFiled: April 19, 2000Date of Patent: December 12, 2006Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard Herman Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Publication number: 20060104975Abstract: C-type lectins are involved in the binding of many different types of carbohydrates. Considering their diversity in kind and expression of different types of cells, the influence of such binding is very diverse and dependent among others on the type of cell, the environment of the cell and the type of carbohydrate bound. In the present invention new carbohydrate specificities of C-type lectins are disclosed. Interference with this binding property has uses in the prevention of pathogen binding and also in influencing signaling pathways in the C-type lectin containing cell, particularly in Toll like receptor expressing cells such as dendritic cells. Also provided is the use of the carbohydrate specificity to enhance antigen presentation by antigen presenting cells and to manipulate migration of C-type lectin containing cells and the interaction of C-type lectin expressing cells with cellular ligands on neighboring cells.Type: ApplicationFiled: November 7, 2003Publication date: May 18, 2006Inventors: Teunis Bernard Geijtenbeek, Yvette Van Kooyk
-
Publication number: 20050220804Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: ApplicationFiled: July 23, 2003Publication date: October 6, 2005Inventors: Carl Figdor, Teunis Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Publication number: 20050118168Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: ApplicationFiled: July 23, 2003Publication date: June 2, 2005Inventors: Carl Figdor, Teunis Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Publication number: 20040091481Abstract: The invention relates to the use of a compound that binds to a C-type lectin on the surface of a sinusoid endothelial layer, in the preparation of a composition for modulating, in particular reducing, the immune response in animal, in particular a human or another mammal. The sinusoid endothelial layer may be either constituted by liver sinusoid endothelial cells (LSEC) or by the lymph node sinusoidal zone.Type: ApplicationFiled: November 17, 2003Publication date: May 13, 2004Inventors: Carl Gustav Figdor, Teunis Bernard Herman Geitjenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Publication number: 20030064071Abstract: The present invention demonstrates that a receptor, named DC-SIGN, is specifically expressed on dendritic cells, and facilitates infection of T lymphocytes with HIV. Assays for identifying compounds that modulate the interaction of DC-SIGN and HIV and/or T cells and macrophage are provided. Compounds so identified are also part of the present invention.Type: ApplicationFiled: May 20, 2002Publication date: April 3, 2003Inventors: Dan R. Littman, Douglas Kwon, Yvette Van Kooyk, Teunis Geijtenbeek
-
Patent number: 6391567Abstract: The present invention demonstrates that a receptor, named DC-SIGN, is specifically expressed on dendritic cells, and facilitates infection of T lymphocytes with HIV. Assays for identifying compounds that modulate the interaction of DC-SIGN and HIV and/or T cells and macrophage are provided. Compounds so identified are also part of the present invention.Type: GrantFiled: March 2, 2000Date of Patent: May 21, 2002Assignee: New York UniversityInventors: Dan R. Littman, Douglas Kwon, Yvette Van Kooyk, Teunis Geijtenbeek